Organogenesis Holdings Inc. (ORGO) News
Filter ORGO News Items
ORGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ORGO News Highlights
- ORGO's 30 day story count now stands at 8.
- Over the past 6 days, ORGO's stories per day has been in a clear downtrend, falling by about 0.23 per day.
- DOW, MPAA and NOTE are the most mentioned tickers in articles about ORGO.
Latest ORGO News From Around the Web
Below are the latest news stories about ORGANOGENESIS HOLDINGS INC that investors may wish to consider to help them evaluate ORGO as an investment opportunity.
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2022 Earnings Call TranscriptOrganogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Welcome, ladies and gentlemen to the Fourth Quarter and Fiscal Year 2022 Earnings Conference Call for Organogenesis Holdings Inc. Please note that this conference call is being recorded and that the recording will be available on the company’s website for replay shortly. […] |
Why Shares of Unisys, Organogenesis, and Motorcar Parts of America Fell TodayShares of Unisys (NYSE: UIS), Organogenesis Holdings (NASDAQ: ORGO), and Motorcar Parts of America (NASDAQ: MPAA) fell today as all three stocks were removed from the S&P SmallCap 600 index as part of its quarterly rebalancing. Unisys closed the day down 14.1%, Organogenesis lost 18.5%, and Motorcar Parts of America gave up 12.2%. There are several reasons stocks fall when they're removed from a major index like the S&P SmallCap 600. |
Organogenesis Holdings Full Year 2022 Earnings: Revenues DisappointOrganogenesis Holdings ( NASDAQ:ORGO ) Full Year 2022 Results Key Financial Results Revenue: US$450.9m (down 3.5% from... |
Fair Isaac & Co. Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 20, to coincide with the quarterly rebalance. The changes are being made to ensure each index is more representative of its market capitalization range. The company moving to the S&P 500 is more representative of the large-cap market space. All companies moving to the S&P MidCap 400 are more representative of the mid |
Q4 2022 Organogenesis Holdings Inc Earnings CallQ4 2022 Organogenesis Holdings Inc Earnings Call |
Organogenesis (ORGO) Q4 2022 Earnings Call TranscriptWelcome, ladies and gentlemen, to the fourth quarter and fiscal year 2022 earnings conference call for Organogenesis Holdings Inc. At this time, all participants have been placed in listen-only mode. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A Risk Factors of the company's most recent annual report and its subsequently filed quarterly reports. You are cautioned not to place undue reliance upon any forward-lookin... |
Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 GuidanceCANTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022. Fourth Quarter 2022 Financial Results Summary: Net revenue of $115.5 million for the fourth quarter of 2022, a decrease |
Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee OsteoarthritisCANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today reported the favorable outcome of the interim analysis of its Phase 3 clinical trial for the management of symptoms associated with knee osteoarthritis. The pre-specified interim analysis on 50% of the 474 |
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2022 financial results will be reported after the market closes on Wednesday, March 1st. Management will host a conference call at 5:00 p.m. Eastern Time on Marc |
Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech ConferenceCANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference, which is being held at The Fontainebleau Miami Beach in Mi |